Novartis Pharmaceuticals Patents – Key Insights and Stats

Novartis Pharmaceuticals has a total of 191 patents globally, out of which 112 have been granted. Of these 191 patents, more than 40% patents are active. The United States of America is where Novartis Pharmaceuticals has filed the maximum number of patents, followed by the United Kingdom and Australia. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Novartis Pharmaceuticals.

Novartis Pharmaceuticals is a sub-part of Novartis was founded in the year 1996. Novartis Pharmaceuticals operates as a pharmaceutical company. The business conducts research, develops, produces, and markets patent-protected prescription medications for critical medical conditions including the heart, central nervous system, cancer, ophthalmology, organ transplantation, and respiratory systems.

Do read about some of the most popular patents of Novartis Pharmaceuticals which have been covered by us in this article and also you can find Novartis Pharmaceuticals patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Novartis Pharmaceuticals patent portfolio.

How many patents does Novartis Pharmaceuticals have?

Novartis Pharmaceuticals has a total of 191 patents globally. These patents belong to 93 unique patent families. Out of 191 patents, 78 patents are active.

How Many Patents did Novartis Pharmaceuticals File Every Year?

Novartis Pharmaceuticals Patents Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantNovartis Pharmaceuticals Applications FiledNovartis Pharmaceuticals Patents Granted
20221
202146
202022
201982
201854
201712
2016148
20152012
201489
2013159
2012711
20111011

How many Novartis Pharmaceuticals patents are Alive/Dead?

Novartis Pharmaceuticals Patents Portfolio

How Many Patents did Novartis Pharmaceuticals File in Different Countries?

Novartis Pharmaceuticals Worldwide Patents

Countries in which Novartis Pharmaceuticals Filed Patents

CountryPatents
United States Of America181
United Kingdom1
Australia1
Europe1

Where are the Research Centres of Novartis Pharmaceuticals Patents Located?

Research Centres of Novartis Pharmaceuticals Patents

10 Best Novartis Pharmaceuticals Patents

US7682219B2 is the most popular patent in the Novartis Pharmaceuticals portfolio. It has received 697 citations so far from companies like Monsanto Technology, Athenix Corp, and Agrigenetics.

Below is the list of 10 most cited patents of Novartis Pharmaceuticals:

Publication NumberCitation Count
US6403865B1697
US8415355B2107
US8685980B297
US6537524B196
US7314938B283
US6338407B282
US8168655B277
US8080562B277
US6887459B170
US8084047B265

How many inventions of other companies were rejected due to Novartis Pharmaceuticals patents?

The statistics below share strategic R&D insights. It tells the companies that were trying to protect inventions similar to Novartis Pharmaceuticals invention. They couldn’t because Novartis Pharmaceuticals had protected those before them.

Examiners at the USPTO referred 39 Novartis Pharmaceuticals patents in 147 rejections (35 USC § 102 or 35 USC § 103 types).

The top citing companies in the Novartis Pharmaceuticals patent portfolio are Nissan Chemical, Silvergate Pharmaceuticals, and Dupont.

List of the Companies whose Patents were rejected citing Novartis Pharmaceuticals –

CompanyNumber of Patent Applications that faced Rejection Citing Novartis Pharmaceuticals PatentsNumber of Rejections (102 & 103)
Nissan Chemical1018
Silvergate Pharmaceuticals55
Dupont412
Eci Pharmaceuticals35
Astex34
Supernus Pharmaceuticals36
Rush University Medical Center26
Crystal Pharmatech23
National Jewish Health22
Mankind Pharma24

Count of 102 and 103 Type Rejections based on Novartis Pharmaceuticals Patents

Top Novartis Pharmaceuticals Patents used in Rejecting Most Patent Applications

Patent NumberCount of Rejected Applications
US7371865B211
US20100222334A19
US8080562B25
US9220631B25
US7037525B24
US6410329B14
US8877938B22
US8575146B22
US8410131B22
US20100233253A12
US8685980B22
US6537524B12
US9045457B22
US8119148B22
US9708303B22

What Percentage of Novartis Pharmaceuticals US Patent Applications were Granted?

Novartis Pharmaceuticals (Excluding its subsidiaries) has filed 304 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 156 have been granted leading to a grant rate of 59.54%.

Below are the key stats of Novartis Pharmaceuticals patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for Novartis Pharmaceuticals?

Law FirmTotal ApplicationsSuccess Rate
Novartis23269.30%
Shire C O Troutman Sanders170%
Cooley962.50%
Troutman Pepper90%
K&L Gates5100%
Mccarter & English425%
Fish & Richardson3100%
Genomics Institute3100%
Dechert20%
Dentons2100%

What are Novartis Pharmaceuticals key innovation segments?

What Technologies are Covered by Novartis Pharmaceuticals?

The chart below distributes patents filed by Novartis Pharmaceuticals in different countries on the basis of the technology protected in patents. It also represents the markets where Novartis Pharmaceuticals thinks it’s important to protect particular technology inventions.

R&D Focus: How has Novartis Pharmaceuticals search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Novartis Pharmaceuticals?

Updated on January 19, 2023

Was this article helpful?

Leave a Comment